Tonix Pharmaceuticals Holding Corp.
No SEC Form 4 filings for $TNXP in the last 30 days.
See all $TNXP insider activity →Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.
Tonix Pharmaceuticals Holding reported Q2 2026 revenue of about $13.544M, up from $1.998M a year earlier, largely driven by TONMYA sales (about $11M). The company posted a net loss of about $40.552M, and basic EPS loss narrowed to $2.44. The stock fell about 2% on the day.
Tonix Pharmaceuticals (NASDAQ: TNXP) reported Q2 2026 net product revenue of about $13.5M versus $2M a year earlier, driven by $11M in TONMYA sales. TONMYA generated 12,592 prescriptions, with new prescriptions up 36% and refills up 207%. Cash and equivalents were about $176.2M, expected to fund operations into early Q2 2027.
Over the past 7 days, alphai's AI scored 4 news stories mentioning TNXP (Tonix Pharmaceuticals Holding Corp.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent TNXP coverage spans earnings and financial news.
The call provides fresh, decision-relevant operating metrics for TONMYA commercialization plus updated development and cash runway details.
The quarter shows a sharp revenue ramp but reinforces cash-burn risk, likely keeping TNXP trading on funding/runway expectations rather than sales alone.
Strong TONMYA commercial traction plus pipeline enrollment and cash runway into early Q2 2027 are near-term positive catalysts for TNXP.
Earnings-call disclosures point to accelerating commercial traction for TONMYA and ongoing clinical progress for TNX-4800 and TNX-102SL, supporting a constructive near-term risk/reward.
Near-term focus is commercial execution for Tonmya (payer coverage and field-force ramp) plus pipeline de-risking via FDA feedback and trial start timing.
alphai scores every news story that mentions TNXP with an AI model for sentiment and relevance, and aggregates insider trades from Tonix Pharmaceuticals Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.
6 min readTonix Pharmaceuticals Holding reported Q2 2026 revenue of about $13.544M, up from $1.998M a year earlier, largely driven by TONMYA sales (about $11M). The company posted a net loss of about $40.552M, and basic EPS loss narrowed to $2.44. The stock fell about 2% on the day.
6 min readTonix Pharmaceuticals (NASDAQ: TNXP) reported Q2 2026 net product revenue of about $13.5M versus $2M a year earlier, driven by $11M in TONMYA sales. TONMYA generated 12,592 prescriptions, with new prescriptions up 36% and refills up 207%. Cash and equivalents were about $176.2M, expected to fund operations into early Q2 2027.
5 min readTonix Pharmaceuticals (TNXP) discussed Q2 2026 results and pipeline updates on its earnings call. CEO Seth Lederman said TONMYA net sales were about $11M, up 197% QoQ, with 12,592 prescriptions and rising refills. Coverage was 136M lives (43% U.S.). For TNX-4800 Lyme prevention, the company said Phase 2 could be pivotal if enough placebo events accrue.
7 min readTonix Pharmaceuticals (NASDAQ:TNXP) reported Q2 call updates on Tonmya market access. Coverage was about 136M lives (43%) and is expected to rise to ~145M (46%) from a Jan. 1, 2027 GPO deal. Tonix added 50 sales reps, targeting ~150 by September. Pipeline: HORIZON Phase II TNX-102 SL in MDD (enroll ~360) and Lyme prevention Phase II (enroll ~3,300). Cash: ~$176.2M.
4 min readTonix Pharmaceuticals (NASDAQ: TNXP) reported Q2 2026 net product revenue of about $13.5M versus $2M a year earlier, driven by TONMYA net sales of about $11M. TONMYA prescriptions totaled 12,592, up 100% sequentially. TONMYA coverage is ~136M lives, rising to ~145M from Jan. 1, 2027. Cash was ~$176.2M.
4 min readTonix Pharmaceuticals Holding Corp. (TNXP) reported Q2 2026 revenue growth attributed to Tonmya’s launch, broader market access, and refill dynamics. The company said pipeline programs advanced, including pivotal studies for MDD and Lyme disease prevention. Tonix also stated its cash runway extends into early Q2 2027, per its Q2 2026 audio transcript.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 ex99-01.htm EX-99.01 Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for
7 min readTonix Pharmaceuticals (Nasdaq: TNXP) reported Q2 2026 net product revenue of about $13.5M, up from $2.0M a year earlier, driven by TONMYA sales of about $11.0M and migraine products Zembrace SymTouch and Tosymra. TONMYA prescriptions rose to 12,592 and coverage expanded to ~136M lives. Cash was ~$176.2M at June 30, 2026; net loss was $40.6M.
6 min readTonix Pharmaceuticals Holding (TNXP) is expected to report Q2 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts forecast revenue of $7,876,950 and EPS of -$2.75. The article cites recent TNXP insider purchases and 13F activity, plus two analysts’ price targets with a $24.0 median.
4 min read
